Pomalidomide in the treatment of multiple myeloma: design, development and place in therapy

Multiple myeloma is a very heterogeneous disease with variable survival. Despite recent progress and the widespread use of new agents, patients with relapsed and refractory disease have a poor outcome. Immunomodulatory drugs play a key role in both the front-line and the relapsed/refractory setting....

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Drug Des Devel Ther
Autors principals: Ríos-Tamayo, Rafael, Martín-García, Agustín, Alarcón-Payer, Carolina, Sánchez-Rodríguez, Dolores, de la Guardia, Ana María del Valle Díaz, García Collado, Carlos Gustavo, Jiménez Morales, Alberto, Jurado Chacón, Manuel, Cabeza Barrera, José
Format: Artigo
Idioma:Inglês
Publicat: Dove Medical Press 2017
Matèries:
Review
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5574598/
https://ncbi.nlm.nih.gov/pubmed/28860711
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/DDDT.S115456
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars